Search

everythinglearnresearchcommunity

for

Search:↓

Dermoscopy can help assess the severity of chronic radiation-induced skin damage in head and neck cancer patients.

Radiotherapy can cause skin fibrosis, which is often overlooked and needs better treatment and evaluation.

Temozolomide improves survival in grade III glioma patients without harming quality of life.

The model effectively mimics radiation-induced skin damage for future research.

After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.

Scalp cooling prevented hair loss in half of the patients, despite significant side effects.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Photobiomodulation therapy helps manage cancer treatment side effects but needs more research for optimization.

Partial hair-sparing brain radiotherapy is possible and doesn't affect cancer control but still causes noticeable hair loss.

Early detection and multidisciplinary management of skin and mouth side effects from breast cancer treatments improve patient outcomes.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.

Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.

HDR electronic brachytherapy effectively treats nonmelanoma skin cancer with good cosmetic results and minimal side effects.

Hippocampus sparing whole brain radiation therapy prevents hair loss and preserves cognitive function.

Radiation damages salivary glands by harming blood vessels, but antioxidants might help protect them.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Radiation therapy damages skin structure and immune function, causing inflammation and potential hair loss.

Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.

A standardized scoring system is needed to improve model reliability for predicting hair loss in brain tumor patients treated with proton therapy.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

The Italian version of a relationship scale was adapted for cancer patients, showing some differences from the original and suggesting its use could improve therapy and treatment adherence.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Slovak breast cancer survivors have moderate quality of life, with emotional and cognitive strengths but social and physical challenges, needing targeted support.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

The CWARTS tool is a promising method for assessing warts and could improve treatment and research.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

The Bethesda system is effective for identifying thyroid cancer but has low sensitivity.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.